Early molecular imaging of interstitial changes in patients after myocardial infarction: Comparison with delayed contrast-enhanced magnetic resonance imaging

Journal of Nuclear Cardiology

Volumn 17, Issue 6, 2010, Pages 1065-1072

  Verjans, Johan ^a   Wolters, Sander ^a   Laufer, Ward ^a   Schellings, Mark ^a   Lax, Michelle ^c   Lovhaug, Dagfinn ^d   Boersma, Hendrikus ^a   Kemerink, Gerrit ^a   Schalla, Simon ^a   Gordon, Paul ^c   Teule, Jaap ^a   Narula, Jagat ^a,b   Hofstra, Leonard ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GE HEALTHCARE   (United Kingdom)

^d GE HEALTHCARE   (Norway)

Author keywords

Heart failure; Infarction; Molecular imaging; Myocardial; SPECT

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; GADOLINIUM; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; INTERMETHOD COMPARISON; MALE; MOLECULAR IMAGING; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PRIORITY JOURNAL; SCAR FORMATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; FEMALE; GADOLINIUM; HEART FAILURE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; PERFUSION; PROSPECTIVE STUDIES; TECHNETIUM TC 99M SESTAMIBI; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78651315319     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-010-9268-5     Document Type: Article

References (25)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
2. Sutton MS. Quantitative echocardiography in left ventricular remodeling after myocardial infarction. Curr Opin Cardiol 1996;11:378-85.
3. Lima JA, Desai MY. Cardiovascular magnetic resonance imaging: Current and emerging applications. J Am Coll Cardiol 2004;44:1164-71.
4. Corday E, Hajduczki I, O'Byrne GT, Kar S, Areeda J, Corday SR. Echocardiographic criteria to distinguish reversible from irreversible myocardial ischaemia. Eur Heart J 1988;9:29-43.
5. Park S, Choi BW, Rim SJ, Shim CY, Ko YG, Kang SM, et al. Delayed hyperenhancement magnetic resonance imaging is useful in predicting functional recovery of nonischemic left ventricular systolic dysfunction. J Card Fail 2006;12:93-9.
6. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1977-85.
7. Bello D, Shah DJ, Farah GM, Di Luzio S, Parker M, Johnson MR, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003;108:1945-53.
8. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-62.
9. Saraste A, Nekolla SG, Schwaiger M. Cardiovascular molecular imaging: An overview. Cardiovasc Res 2009;83(4):643-52.
10. Shirani J, Narula J, Eckelman WC, Narula N, Dilsizian V. Early imaging in heart failure: Exploring novel molecular targets. J Nucl Cardiol 2007;14:100-10.
11. Dilsizian V, Eckelman WC, Loredo ML, Jagoda EM, Shirani J. Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. J Nucl Med 2007;48:182-7.
12. Verjans JWH, Lovhaug D, Narula N, Petrov AD, Indrevoll B, Bjurgert E, et al. Noninvasive imaging of angiotensin receptors after myocardial infarction. JACC Cardiovasc Imaging 2008;1:354-62.
13. van den Borne SW, Isobe S, Verjans JW, Petrov A, Lovhaug D, Li P, et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol 2008;52:2017-28.
14. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2:e70.
15. Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, et al. Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006;47:1434-9.
16. van den Borne SW, Isobe S, Zandbergen HR, Li P, Petrov A, Wong ND, et al. Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC Cardiovasc Imaging 2009;2:187-98.
17. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
18. Kietselaer BL, Reutelingsperger CP, Boersma HH, Heidendal GA, Liem IH, Crijns HJ, et al. Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. J Nucl Med 2007;48:562-7.
19. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
20. Desmouliere A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol 1995;146:56-66.
21. Sun M, Opavsky MA, Stewart DJ, Rabinovitch M, Dawood F, Wen WH, et al. Temporal response and localization of integrins beta1 and beta3 in the heart after myocardial infarction: Regulation by cytokines. Circulation 2003;107:1046-52.
22. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angio- genesis following experimental myocardial infarction. J Clin Invest 2004;113:1684-91.
23. Hua J, Dobrucki LW, Sadeghi MM, Zhang J, Bourke BN, Cava-liere P, et al. Noninvasive imaging of angiogenesis with a 99mTc- labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation 2005;111:3255-60.
24. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767-71. (Pubitemid 37093916)
25. Cohn JN, Tognoni G. A randomized trial of the angiotensin- receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.